Patient preferences for psoriasis treatments: Impact of treatment experience

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 2, 2013, Pages 187-198

  Schaarschmidt, M L ^a   Umar, N ^b   Schmieder, A ^a   Terris, D D ^b,c   Goebeler, M ^a,d   Goerdt, S ^a   Peitsch, W K ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF GEORGIA   (United States)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIPSORIASIS AGENT; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; USTEKINUMAB;

ARTICLE; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; MALE; MONOTHERAPY; PATIENT COMPLIANCE; PATIENT PREFERENCE; PATIENT SATISFACTION; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION ROUTES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT PREFERENCE; PATIENT SATISFACTION; PHOTOTHERAPY; PSORIASIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84872683157     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04440.x     Document Type: Article

References (53)

1. Lebwohl M,. A clinician's paradigm in the treatment of psoriasis. J Am Acad Dermatol 2005; 53: S59-S69.
2. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T,. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9: 136-139.
3. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T,. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-284.
4. DiBonaventura M, Wagner S, Waters H, Carter C,. Treatment patterns and perceptions of treatment attributes, satisfaction and effectiveness among patients with psoriasis. J Drugs Dermatol 2010; 9: 938-944.
5. Poulin Y, Papp KA, Wasel NR, et al. A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis. Int J Dermatol 2010; 49: 1368-1375.
6. Dubertret L, Mrowietz U, Ranki A, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006; 155: 729-736.
7. Nijsten T, Margolis DJ, Feldman SR, Rolstad T, Stern RS,. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol 2005; 52: 434-444.
8. Finlay AY, Ortonne JP,. Patient satisfaction with psoriasis therapies: an update and introduction to biologic therapy. J Cutan Med Surg 2004; 8: 310-320.
9. Renzi C, Picardi A, Abeni D, et al. Association of dissatisfaction with care and psychiatric morbidity with poor treatment compliance. Arch Dermatol 2002; 138: 337-342.
10. Zaghloul SS, Goodfield MJ,. Objective assessment of compliance with psoriasis treatment. Arch Dermatol 2004; 140: 408-414.
11. Richards HL, Fortune DG, O'Sullivan TM, Main CJ, Griffiths CE,. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999; 41: 581-583.
12. Bewley A, Page B,. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol 2011; 25 (suppl 4): 9-14.
13. Nast A, Boehncke WH, Mrowietz U, et al. S3-guidelines for the treatment of psoriasis vulgaris Update 2011. J Dtsch Dermatol Ges 2011; 9 (Suppl 2): 1-104.
14. Langley R, Reich K,. In touch with psoriasis: a patient-centred approach to therapy. J Eur Acad Dermatol Venereol 2011; 25 (Suppl 4): 1-2.
15. Zug KA, Littenberg B, Baughman RD, et al. Assessing the preferences of patients with psoriasis. A quantitative, utility approach. Arch Dermatol 1995; 131: 561-568.
16. Schmitt J, Meurer M, Klon M, Frick KD,. Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study. Br J Dermatol 2008; 158: 351-359.
17. Delfino M, Jr, Holt EW, Taylor CR, Wittenberg E, Qureshi AA,. Willingness-to-pay stated preferences for 8 health-related quality-of-life domains in psoriasis: a pilot study. J Am Acad Dermatol 2008; 59: 439-447.
18. Opmeer BC, Heydendael VM, deBorgie CA, et al. Patients with moderate-to-severe plaque psoriasis preferred oral therapies to phototherapies: a preference assessment based on clinical scenarios with trade-off questions. J Clin Epidemiol 2007; 60: 696-703.
19. Seston EM, Ashcroft DM, Griffiths CE,. Balancing the benefits and risks of drug treatment: a stated-preference, discrete choice experiment with patients with psoriasis. Arch Dermatol 2007; 143: 1175-1179.
20. Schaarschmidt M-L, Schmieder A, Umar N, et al. Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes. Arch Dermatol 2011; 147: 1285-1294.
21. Schmieder A, Schaarschmidt M-L, Umar N, et al. Comorbidities significantly impact patients' preferences for psoriasis treatments. J Am Acad Dermatol. 2011; [Epub ahead of print].
22. Kjaer T, Bech M, Gyrd-Hansen D, Hart-Hansen K,. Ordering effect and price sensitivity in discrete choice experiments: need we worry? Health Econ 2006; 15: 1217-1228.
23. Claes C, Kulp W, Greiner W, Graf von der Schulenberg J, Werfel T,. Therapie der mittelschweren und schweren Psoriasis. In Medizinwissen, HTA-Bericht 34;, Rüther A, Göhlen B, eds. German Institute for Medical Documentation and Information, Köln, Germany, 2006: vol. 34, 15-46, 91-94.
24. Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004; 2: 12.
25. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
26. Puzenat E, Bronsard V, Prey S, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature J Eur Acad Dermatol Venereol 2010; 2: 10-16.
27. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010; 62: 114-135.
28. Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349: 658-665.
29. Mrowietz U, Altmeyer P, Bieber T, Rocken M, Schopf RE, Sterry W,. Treatment of psoriasis with fumaric acid esters (Fumaderm). J Dtsch Dermatol Ges 2007; 5: 716-717.
30. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61: 451-485.
31. Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010; 340: c147.
32. van deKerkhofPC, Segaert S, Lahfa M, et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderateto-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 2008; 159: 1177-1185.
33. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304-1312.
34. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-115.
35. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-1674.
36. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-1684.
37. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826-850.
38. Blome C, Simianer S, Purwins S, et al. Time needed for treatment is the major predictor of quality of life in psoriasis. Dermatology 2010; 221: 154-159.
39. Revicki DA, Menter A, Feldman S, Kimel M, Harnam N, Willian MK,. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled phase III study. Health Qual Life Outcomes 2008; 6: 75.
40. Lebwohl M, Papp K, Han C, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol 2010; 162: 137-146.
41. Papp KA, Poulin Y, Bissonnette R, et al., Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol 2010; [Epub ahead of print].
42. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374.
43. Reich K, Nestle FO, Papp K, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol 2006; 154: 1161-1168.
44. Katugampola RP, Lewis VJ, Finlay AY,. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol 2007; 156: 945-950.
45. Lecluse LL, Tutein Nolthenius JL, Bos JD, Spuls PI,. Patient preferences and satisfaction with systemic therapies for psoriasis: an area to be explored. Br J Dermatol 2009; 160: 1340-1343.
46. Christophers E, Griffiths CE, Gaitanis G, van de Kerkhof P,. The unmet treatment need for moderate to severe psoriasis: results of a survey and chart review. J Eur Acad Dermatol Venereol 2006; 20: 921-925.
47. Mrowietz U, Kragballe K, Nast A, Reich K,. Strategies for improving the quality of care in psoriasis with the use of treatment goals-a report on an implementation meeting. J Eur Acad Dermatol Venereol 2011; 25 (Suppl 3): 1-13.
48. Jones-Caballero M, Unaeze J, Penas PF, Stern RS,. Use of biological agents in patients with moderate to severe psoriasis: a cohort-based perspective. Arch Dermatol 2007; 143: 846-850.
49. Mahler R, Jackson C, Ijacu H,. The burden of psoriasis and barriers to satisfactory care: results from a Canadian patient survey. J Cutan Med Surg 2009; 13: 283-293.
50. Driessen RJ, Bisschops LA, Adang EM, Evers AW, Van De Kerkhof PC, De JongEM,. The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics. Br J Dermatol 2010; 162: 1324-1329.
51. Bhosle MJ, Feldman SR, Camacho FT, Timothy Whitmire J, Nahata MC, Balkrishnan R,. Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis. J Dermatolog Treat 2006; 17: 294-301.
52. Perneger TV,. What's wrong with Bonferroni adjustments. BMJ 1998; 316: 1236-1238.
53. Bender R, Lange S,. Multiple test procedures other than Bonferroni's deserve wider use. BMJ 1999; 318: 600-601.